Back to search

Netherlands· NL-8aacf999a1f1

Adjupanrix, (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals, suspensie en emulsie voor emulsie voor injectie

A influenza, inaktiviert, spalt/split virus oder oberflächen-antigen product containing influenzavaccin a-vietnam-1194-2004 nibrg-14 (h5n1), geinactiveerd, splitvaccin, registered in Netherlands by GlaxoSmithKline Biologicals S.A.. The same ATC class is registered in 11 of our 19 countries.

ATC J07BB02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedAdjupanrix, (H5N1) (split virion, in…ATCJ07BB02REGISTER NO.NL-8aacf999a1f1PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen is registered in 11 of 19 countries.

Countries holding a registration under ATC J07BB02 (influenza, inaktiviert, spalt/split virus oder oberflächen-antigen), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen · ATC J07BB02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
INFLUENZAVACCIN A-VIETNAM-1194-2004 NIBRG-14 (H5N1), GEINACTIVEERD, SPLITVACCIN
Manufacturer
GlaxoSmithKline Biologicals S.A.
Country
Netherlands (NL)
ATC code
J07BB02
ATC class
Influenza, inaktiviert, Spalt/Split Virus oder Oberflächen-Antigen
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/09/578

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5f0d4a9c-afb8-4471-86c7-e12eb15a4af4
GET /v1/drugs/5f0d4a9c-afb8-4471-86c7-e12eb15a4af4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Suspensie voor injectie, Emulsie voor injectie",
  "route": "Intramusculair gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/adjupanrix-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Influenza, Purified Antigen",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp105779",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 12-WATER (E 339)",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
    "MAGNESIUMCHLORIDE 6-WATER (E 511)",
    "NATRIUMCHLORIDE",
    "OCTOXINOL",
    "POLYSORBAAT 80 (E 433)",
    "POLYSORBAAT 80 (E 433)",
    "SQUALEEN",
    "THIOMERSAL",
    "TOCOFEROL, DL-ALFA (E 307)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "INFLUENZAVACCIN A-VIETNAM-1194-2004 NIBRG-14 (H5N1), GEINACTIVEERD, SPLITVACCIN"
  ],
  "leaflet_url": null,
  "authorised_at": "2009/11/05",
  "procedure_number": "EMEA/H/C/001206",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/09/578",
  "additional_monitoring": "N"
}

See everything about influenza, inaktiviert, spalt/split virus oder oberflächen-antigen.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.